Compass Pathways is a healthcare company focused on developing innovative therapies for mental health conditions. Its core product is psilocybin therapy, aimed at treating treatment-resistant depression and other mental health disorders. The company operates primarily in the biotechnology segment, with revenue sources stemming from research and development collaborations, clinical trials, and potential future product sales.
The investment profile of Compass Pathways is more aligned with growth investors, given its focus on innovative therapies and potential market expansion. The company currently does not offer dividends, and its financial metrics indicate a higher risk profile. Investors may consider the stock for its long-term growth potential, while being aware of the inherent volatility and uncertainties in the biotech sector.
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-06-09 02:36 | Acheter | Conserver | High risk with uncertain fundamentals and negative momentum. |
| 2026-06-03 02:37 | Conserver | Acheter | High volatility; uncertain fundamentals warrant caution. |
| 2026-05-08 15:32 | — | Conserver | High volatility with negative earnings and uncertain fundamentals. |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-05-15 12:45 | Maxim Group | Objectif relevé | 12 → 20 | 10.3956 |
| 2026-05-14 12:07 | Morgan Stanley | Objectif relevé | 16 → 17 | 10.94 |
| 2026-05-07 14:26 | UBS | Mettre à jour | — → 18 | 9.2637 |
